Table of Contents Author Guidelines Submit a Manuscript
International Journal of Alzheimer’s Disease
Volume 2010, Article ID 109618, 5 pages
Review Article

Perfusion Imaging with SPECT in the Era of Pathophysiology-Based Biomarkers for Alzheimer's Disease

1Department for Psychiatry and Psychiatry, University of Erlangen-Nuermberg, Schwabachanlage 6, 91054 Erlangen, Germany
2Clinic of Nuclear Medicine, University of Erlangen-Nuermberg, Schwabachanlage 6, 91054 Erlangen, Germany

Received 8 October 2010; Accepted 15 November 2010

Academic Editor: Adam S. Fleisher

Copyright © 2010 Markus Weih et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


SPECT allows registration of regional cerebral blood flow (rCBF) which is altered in a characteristic temporoparietal pattern in Alzheimer's Dementia. Numerous studies have shown the diagnostic value of reduced cerebral blood flow and metabolic changes using perfusion SPECT and FDG-PEPT in AD diagnosis as well as in differential diagnosis against frontotemporal dementia, dementia with Lewy bodies and vascular disease. Recently more pathophysiology-based biomarkers in CSF and Amyloid-PET tracers have been developed that probably have a higher diagnostic accuracy than the more indirect rCBF changes seen in perfusion SPECT. In the paper review, we describe recent advances in AD biomarkers as well as improvements in the SPECT technique.